Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DW1029M and Linagliptin Interaction Study
NCT02212782Phase 1Completed
- Sponsor
- Dongwha Pharmaceutical Co., Ltd.
- Start
- Sep 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DW1029M in diabetic nephropathy (DN) (2 arms), sponsored by Dongwha Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at Day 49 and Area Under the Curve at Day 49. Started Sep 2014; status: completed.
02
Drugs
DW1029M
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT02212782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02212782.